Main NAV exp frag
Global Nav Exp Frag

Indication

 

About ONUREG®

Why ONUREG?
 

How was ONUREG studied?

ONUREG was studied in a large clinical trial
 

Check
  • ONUREG was tested against placebo
    • A placebo is an inactive medicine that can help test the effectiveness of a new treatment in a clinical trial
  • 238 people were treated with ONUREG and 234 people were treated with placebo
  • People in the trial were between 55 and 86 years old
  • Everyone was in first remission following intensive induction chemotherapy with or without consolidation therapy
  • The trial only included people who were not planning to receive a transplant

ONUREG helped patients like you live longer

People treated with ONUREG had longer median overall survival

Half the people in the trial were still alive at:

Median overall survival


Additional results*
from the study showed:
 

Estimated overall survival

~Three out of four (73%) people who received ONUREG were alive at one year

~Two out of four (56%) people who received placebo were alive at one year

These outcomes were experienced by people in the ONUREG clinical trial. Your results may vary.

* Important to know: Estimated overall survival results should be viewed with caution. The ONUREG trial was designed to compare median overall survival with ONUREG versus placebo. It was not designed to compare survival at other time points.

 

What is overall survival?

 

Overall survival

Overall survival is an important data point that is one way to show how well a treatment works in a clinical trial

  • It represents the length of time that a person lives after starting a medication
  • When an AML medication achieves longer overall survival, it offers people the chance for more life
Overall survival

In the ONUREG clinical trial, median overall survival was used to compare:

The length of time when 50% (or half) the people treated with ONUREG were still alive

vs

The length of time when 50% (or half) the people treated with placebo were still alive